DOI

This work is devoted to the study of biocompatibility, cyto- and genotoxicity, mechanism of action and prospects for the use of atranorin, which is an AKT kinase inhibitor, for the treatment of myelodysplastic syndrome. Atra- norin was isolated by preparative flash chromatography; identification was carried out by UV, IR, and NMR spec- troscopy, mass spectrometry, and elemental analysis. Biocompatibility studies included studies of haemocompat- ibility, genotoxicity, antioxidant activity, cytotoxicity against ECV340 and HEK293 cell lines. Computer model- ling of the interaction of atranorin with AKT kinase was carried out using docking followed by molecular dynam- ics of the resulting complexes; the ADMET properties of atranorin were also calculated. Flow cytometry included analysis of the expression level of PD-L1 and TIM-3 in the presence of atranorin on THP-1, Mono-Mac-1 and KG-1 cell lines, as well as human bone marrow cells.
Переведенное названиеАтранорин как новая потенциальная субстанция для лечения миелодиспластического синдрома
Язык оригиналаанглийский
Номер статьи125743
Число страниц16
ЖурналJournal of Molecular Liquids
Том413
Дата раннего онлайн-доступа1 авг 2024
DOI
СостояниеОпубликовано - 1 ноя 2024

    Области исследований

  • Atranorin, Biocompatibility, Cytotoxicity, AKT kinase, Genotoxicity

ID: 123590383